Supplementary Figure 1 from Pomalidomide and Lenalidomide Induce p21<sup>WAF-1</sup> Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism
Laure Escoubet‐Lozach, Dominique Verhelle(Pfizer (United States)), I-Lin Lin, Peter J. Worland, Kristen Jensen-Pergakes, Peter Schäfer(Bristol-Myers Squibb (United States)), Kyle Chan, Helen Brady, George W. Muller(University of Leeds), Anita K. Gandhi(Bristol-Myers Squibb (United States))
Cited by 0
Related Papers
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
|Blood|2001|905
Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate <scp>T</scp> cells by inducing degradation of <scp>T</scp> cell repressors <scp>I</scp> karos and <scp>A</scp> iolos via modulation of the <scp>E</scp> 3 ubiquitin ligase complex <scp>CRL</scp> 4 <scp> <sup>CRBN</sup> </scp>
|British Journal of Haematology|2013|619
Identification of a selenocysteyl-tRNASer in mammalian cells that recognizes the nonsense codon, UGA
|Journal of Biological Chemistry|1989|285